Personalized dose selection platform for patients with solid tumors in the PRECISE CURATE.AI feasibility trial

Agata Blasiak, Anh T. L. Truong, Nigel Foo, Lester W. J. Tan, Kirthika S. Kumar, Shi-Bei Tan, Chong Boon Teo, Benjamin Tan Kye Jin, Xavier Tadeo Campillo, Hon Lyn Tan, Cheng Ean Chee, Wei Peng Yong, Dean Ho, Raghav Sundar

Keywords: solid tumor, capecitabine, personalized dosing, case study, case series, clinical decision support, AI-derived

TL;DR: CURATE.AI is an AI platform that personalizes dosing based on a patient’s small dataset. The PRECISE CURATE.AI trial showed its adaptability, high user adherence, and strong physician involvement, for solid tumor treatment with capecitabine.

Confirmation Of Submission Requirements: I submit a previously published paper. It was published in an archival peer–reviewed venue on or after September 8th 2024, I specify the DOI in the field below, and I submit the camera-ready version of the paper.

DOI: https://doi.org/10.1038/s41698-025-00835-7

Submission Number: 77